Sifat Sharmin

The Royal Melbourne Hospital — Australia

Medicine · Health Sciences

20h-index1.8kcitations98works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(66), Peripheral Neuropathies and Disorders(17), Polyomavirus and related diseases(13), Rheumatoid Arthritis Research and Therapies(12), COVID-19 epidemiological studies(6)

Publications98 total

Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis
European Journal of Neurology·2026Open Access
Managing reactivation of multiple sclerosis during treatment with natalizumab
Multiple Sclerosis Journal·2025Open Access
3614 Preserving neurological function in people at high and low risk of aggressive multiple sclerosis
2025Open Access
CS11 The effect of high-efficacy therapy on disability in children with multiple sclerosis
2025Open Access
CS7 Treatment de-escalation in relapsing remitting multiple sclerosis — an observational study
2025Open Access
Health-seeking behavior and anxiety of cancer patients in Bangladesh during the COVID-19 pandemic: A cross-sectional study
Journal of Family Medicine and Primary Care·2025Open Access
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
Brain·2025· 2 citedOpen Access
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Journal of Neurology Neurosurgery & Psychiatry·2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis
JAMA Neurology·2025· 20 citedOpen Access
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study
Journal of Neurology·2025· 1 citedOpen Access
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study
CNS Drugs·2025· 6 citedOpen Access
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD
Neurology·2024· 16 cited
Oral hygiene practice, status, and periodontitis among dental outpatient elderly in tertiary hospitals: a cross-sectional study in Dhaka, Bangladesh
2024Open Access
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Journal of Neurology Neurosurgery & Psychiatry·2024· 10 citedOpen Access
Health-Seeking Behavior and Anxiety of Cancer Patients in Bangladesh during the COVID-19 Pandemic: A Cross-Sectional Study
2024· 2 citedOpen Access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Multiple Sclerosis Journal·2024· 13 citedOpen Access
3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
2024Open Access
3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
2024Open Access
Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis
Brain and Behavior·2024· 3 citedOpen Access
Relapse Determinants in Seropositive and Seronegative Neuromyelitis Optica Spectrum Disorder (P10-14.016)
Neurology·2024
page 1 of 5Next →

Frequent Co-authors

Tomáš Kalinčík(39), Helmut Butzkueven(26), Cavit Boz(26), Serkan Özakbaş(26), Alexandre Prat(25), Pierre Grammond(25), Eva Havrdová(24), Sara Eichau(24), Dana Horáková(23), Charles B. Malpas(22), Alessandra Lugaresi(22), Marc Girard(22), Pierre Duquette(22), Raed Alroughani(22), Murat Terzi(22), Guillermo Izquierdo(21), Anneke van der Walt(21), Recai Türkoğlu(21), Pamela McCombe(20), Izanne Roos(20)